Eli Lilly has released a new plan that will allow self-spend patients to purchase the weight-loss drug Zepbound for as small as $399 each month—below fifty percent the checklist price of other incretin medicines utilized for individuals with obesity.Alongside the announcement of its new program, Lilly also released an “open up letter” indicat… Read More